Puzzling out iron complications in cancer drug resistance.

Abstract

Iron metabolism are frequently disrupted in cancer. Patients with cancer are prone to anemia and receive transfusions frequently; the condition which results in iron overload, contributing to serious therapeutic complications. Iron is introduced as a carcinogen that may increase tumor growth. However, investigations regarding its impact on response to chemotherapy, particularly the induction of drug resistance are still limited. Here, iron contribution to cell signaling and various molecular mechanisms underlying iron-mediated drug resistance are described. A dual role of this vital element in cancer treatment is also addressed. On one hand, the need to administer iron chelators to surmount iron overload and improve the sensitivity of tumor cells to chemotherapy is discussed. On the other hand, the necessary application of iron as a therapeutic option by iron-oxide nanoparticles or ferroptosis inducers is explained. Authors hope that this paper can help unravel the clinical complications related to iron in cancer therapy.

• Authors: Marjan Abedi, Soheila Rahgozar
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 178 Pg. 103772 (Oct 2022) ISSN: 1879-0461 [Electronic] Netherlands
• PMID: 35914667 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022. Published by Elsevier B.V.

Chemical References

• Carcinogens
• Iron Chelating Agents
• Oxides
• Iron

Topics

• Carcinogens
• Drug Resistance, Neoplasm
• Humans
• Iron (metabolism, therapeutic use)
• Iron Chelating Agents (therapeutic use)
• Iron Overload (complications, drug therapy)
• Neoplasms (complications, drug therapy, metabolism)
• Oxides (therapeutic use)